Form4insider filings, from the source

SEC Form 4 · accession 0001628280-26-040575

CRESCENT BIOPHARMA, INC. · CBIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Peter Evan Harwin
Director · 10% Owner
Fairmount Funds Management LLC
Director · 10% Owner
Tomas Kiselak
Director · 10% Owner
Period of report
Jun 2, 2026
Accepted (ET)
Jun 3, 2026 · 7:46 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001253689

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F2,F1$17.01Jun 2, 2026A11,050A—Jun 2, 2036Ordinary Shares11,05011,050I

Explanation of responses

Remarks

Fairmount and Fund II may each be deemed a director by deputization of the Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount.